Mesna

General description

Testicular germ cell tumour □ Ovarian germ cell tumour □ Osteosarcoma □ Rhabdomyosarcoma □ Ewing sarcoma.

INN	Mesna
ATC codes	V03AF01
Medicine type	Chemical agent
EML status history	First added in 2009 (TRS 958) for Unspecified malignant neoplasms of unspecified sites Changed in 2015 (TRS 994) for Osteosarcoma of bone or articular cartilage of unspecified sites Changed in 2015 (TRS 994) for Rhabdomyosarcoma primary site Changed in 2015 (TRS 994) for Other specified malignant neoplasms of the ovary Changed in 2015 (TRS 994) for Germ cell tumour of testis Changed in 2015 (TRS 994) for Ewing sarcoma of bone or articular cartilage of unspecified sites Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of unspecified sites Added in 2021 (TRS 1035) for Burkitt lymphoma including Burkitt leukaemia Changed in 2021 (TRS 1035) for Malignant neoplasms of kidney, except renal pelvis
Wikipedia	Mesna
DrugBank	Mesna (Coenzyme M)

Recommendations

- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule
- Oral > Solid > tablet: 400 mg; 600 mg
- Oral > Other: 600 mg
- Oral > Solid > tablet: 400 mg
- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
- Oral > Solid: 400 mg; 600 mg

Indications

Osteosarcoma of bone or articular cartilage of unspecified sites

Rhabdomyosarcoma primary site

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Ewing sarcoma of bone or articular cartilage of unspecified sites

Unspecified malignant neoplasms of unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of kidney, except renal pelvis